Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 68 | 71 | +3 |
| Shares | 39.7M | 42.0M | +2.30M (+5.8%) |
| Value | $272.3M | $201.4M | −$70.9M (−26.0%) |
New holders (7)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 66,750 | $319.7K | 0.00% |
| Simplex Trading, LLC | 26,245 | $125.0K | 0.00% |
| Corton Capital Inc. | 14,460 | $69.3K | 0.03% |
| SG Americas Securities, LLC | 13,866 | $66.0K | 0.00% |
| Verition Fund Management LLC | 13,127 | $62.9K | 0.00% |
| HRT Financial LP | 10,694 | $51.0K | 0.00% |
| Nisa Investment Advisors, LLC | 1,170 | $5.60K | 0.00% |
Sold out (4)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Silverarc Capital Management, LLC | 31,156 | $213.4K |
| T. Rowe Price Investment Management, Inc. | 21,364 | $147.0K |
| Bank of Montreal | 11,379 | $99.2K |
| Russell Investments Group, Ltd. | 1,431 | $9.80K |